Focus:
Analysis
-
![Treating menopause: at last a non-hormonal alternative?]()
Treating menopause: at last a non-hormonal alternative?
Despite the risk of breast cancer from long-term use of HRT to treat hot flushes, there are currently few non-hormonal options for managing bothersome menopause symptoms. However, new research has...
-
![October’s top news stories]()
October’s top news stories
UCB has signed a merger agreement to acquire Ra Pharmaceuticals for $48 per share, totalling $2.1bn in cash, and Novartis has allied with Microsoft to leverage the latter’s AI technology...
-
![Cancer drug discovery: unravelling the mysteries of halichondrin]()
Cancer drug discovery: unravelling the mysteries of halichondrin
A joint Harvard-Eisai project has achieved a breakthrough by fully synthesising the highly potent anti-cancer molecule halichondrin, sourced from marine sponges, at scale. It has taken 30 years of research...
-
![Oncology: Breast cancer leads Twitter mentions in Q3 2019]()
Oncology: Breast cancer leads Twitter mentions in Q3 2019
Pharmaceutical Technology lists the top five terms tweeted in oncology in Q3 2019, based on data from GlobalData’s Influencer Platform.
-
![Drug repurposing: the industry’s all-rounder medicines]()
Drug repurposing: the industry’s all-rounder medicines
Drug repurposing has become a core approach to drug development due to its time and cost saving qualities. This has fuelled the development of all-rounder drugs that work for many...
-
![The fight against malaria: what role can improved R&D play?]()
The fight against malaria: what role can improved R&D play?
To re-focus global efforts on the eradication of malaria, the WHO’s SAGme has compiled a report based on three years of research, which concludes that there is a need for...
-
![Exscientia Q&A: leveraging AI to create bispecific small molecule drugs]()
Exscientia Q&A: leveraging AI to create bispecific small molecule drugs
Creating bispecific small molecule drugs poses huge challenges, but Exscientia has successfully used AI to automate drug discovery and optimise drug design for these complex compounds. Exscientia’s CEO Andrew Hopkins...
-
![Is growth factor protein the future of Parkinson’s treatment?]()
Is growth factor protein the future of Parkinson’s treatment?
A major, multi-year trial of the GDNF protein as a treatment for Parkinson’s disease published its results in February. While the trial did not meet its primary endpoint, other findings...
-
![The UK’s Cancer Drugs Fund: a model for access and reimbursement?]()
The UK’s Cancer Drugs Fund: a model for access and reimbursement?
In 2016, NHS England established the Cancer Drugs Fund to allow UK patients fast access to particularly innovative drugs where the clinical evidence is not sufficiently mature; this is the...
-
![Pharma Technology Focus: the dengue dilemma]()
Pharma Technology Focus: the dengue dilemma
In this issue: dengue fever vaccine controversy, the problem of manipulated data, fixing a broken drug patent system, non-hormonal menopause treatments and much more.
